NEDD4
Basic information
Region (hg38): 15:55826922-55993660
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NEDD4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | 17 | ||||
missense | 61 | 13 | 81 | |||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 1 | 3 | |||
non coding | 1 | |||||
Total | 0 | 0 | 61 | 24 | 14 |
Variants in NEDD4
This is a list of pathogenic ClinVar variants found in the NEDD4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-55829931-A-G | NEDD4-related disorder | Likely benign (Jul 08, 2022) | ||
15-55829975-A-T | Likely benign (Mar 01, 2023) | |||
15-55830580-T-C | not specified | Uncertain significance (Nov 17, 2022) | ||
15-55830589-A-G | Likely benign (Dec 18, 2018) | |||
15-55833032-T-C | not specified | Uncertain significance (Oct 16, 2024) | ||
15-55833039-C-T | Likely benign (Oct 29, 2018) | |||
15-55833091-A-G | not specified | Uncertain significance (Aug 26, 2024) | ||
15-55833092-T-C | not specified | Uncertain significance (Jun 12, 2023) | ||
15-55834067-T-G | not specified | Uncertain significance (Sep 27, 2024) | ||
15-55834082-T-G | not specified | Uncertain significance (Jun 29, 2023) | ||
15-55834113-C-T | Benign (Dec 31, 2019) | |||
15-55834118-C-T | not specified | Uncertain significance (Sep 10, 2024) | ||
15-55834252-T-C | Likely benign (Mar 01, 2023) | |||
15-55837826-A-G | not specified | Uncertain significance (Apr 16, 2024) | ||
15-55837832-C-T | not specified | Uncertain significance (Feb 28, 2023) | ||
15-55838124-G-C | not specified | Uncertain significance (Feb 28, 2024) | ||
15-55840475-G-C | not specified | Uncertain significance (Dec 28, 2022) | ||
15-55840506-G-A | not specified | Uncertain significance (Jun 29, 2022) | ||
15-55840613-C-G | Likely benign (May 17, 2018) | |||
15-55840647-C-G | not specified | Uncertain significance (Mar 25, 2024) | ||
15-55840651-C-T | not specified | Uncertain significance (Dec 03, 2021) | ||
15-55842006-G-C | not specified | Uncertain significance (Sep 02, 2024) | ||
15-55842102-T-C | not specified | Uncertain significance (May 07, 2024) | ||
15-55842123-G-T | not specified | Uncertain significance (May 24, 2024) | ||
15-55847024-T-C | not specified | Uncertain significance (Sep 27, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NEDD4 | protein_coding | protein_coding | ENST00000338963 | 22 | 166825 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.72e-13 | 1.00 | 125597 | 0 | 151 | 125748 | 0.000601 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.225 | 631 | 647 | 0.975 | 0.0000328 | 8195 |
Missense in Polyphen | 207 | 253.86 | 0.81543 | 3182 | ||
Synonymous | -0.185 | 232 | 228 | 1.02 | 0.0000115 | 2331 |
Loss of Function | 4.08 | 32 | 68.4 | 0.468 | 0.00000384 | 805 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000888 | 0.000884 |
Ashkenazi Jewish | 0.000894 | 0.000893 |
East Asian | 0.000984 | 0.000979 |
Finnish | 0.0000925 | 0.0000924 |
European (Non-Finnish) | 0.000621 | 0.000615 |
Middle Eastern | 0.000984 | 0.000979 |
South Asian | 0.000525 | 0.000523 |
Other | 0.00163 | 0.00163 |
dbNSFP
Source:
- Function
- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Specifically ubiquitinates 'Lys-63' in target proteins (PubMed:23644597). Involved in the pathway leading to the degradation of VEGFR-2/KDFR, independently of its ubiquitin-ligase activity. Monoubiquitinates IGF1R at multiple sites, thus leading to receptor internalization and degradation in lysosomes. Ubiquitinates FGFR1, leading to receptor internalization and degradation in lysosomes. Promotes ubiquitination of RAPGEF2. According to PubMed:18562292 the direct link between NEDD4 and PTEN regulation through polyubiquitination described in PubMed:17218260 is questionable. Involved in ubiquitination of ERBB4 intracellular domain E4ICD. Involved in the budding of many viruses. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. Ubiquitinates TNK2 and regulates EGF-induced degradation of EGFR and TNF2. Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046). {ECO:0000269|PubMed:11598133, ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18305167, ECO:0000269|PubMed:18562292, ECO:0000269|PubMed:20086093, ECO:0000269|PubMed:21399620, ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:23644597, ECO:0000269|PubMed:25631046}.;
- Pathway
- Endocytosis - Homo sapiens (human);Tight junction - Homo sapiens (human);Ubiquitin mediated proteolysis - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);IGF-Ncore;miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;miR-targeted genes in squamous cell - TarBase;Proteasome Degradation;Ebola Virus Pathway on Host;Ebola Virus Pathway on Host;EGF-EGFR Signaling Pathway;Signal Transduction;Regulation of PTEN localization;Regulation of PTEN stability and activity;Cytokine Signaling in Immune system;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Downregulation of ERBB4 signaling;Class I MHC mediated antigen processing & presentation;ErbB4 signaling events;EGFR1;PTEN Regulation;PIP3 activates AKT signaling;Signaling by ERBB4;Signaling by Receptor Tyrosine Kinases;Intracellular signaling by second messengers;ISG15 antiviral mechanism;Antiviral mechanism by IFN-stimulated genes;Interferon Signaling;Signaling events mediated by VEGFR1 and VEGFR2
(Consensus)
Recessive Scores
- pRec
- 0.211
Intolerance Scores
- loftool
- 0.553
- rvis_EVS
- 0.3
- rvis_percentile_EVS
- 71.71
Haploinsufficiency Scores
- pHI
- 0.305
- hipred
- Y
- hipred_score
- 0.684
- ghis
- 0.532
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.962
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nedd4
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- protein polyubiquitination;adaptive immune response;outflow tract morphogenesis;endocardial cushion development;ubiquitin-dependent protein catabolic process;protein monoubiquitination;protein targeting to lysosome;lysosomal transport;neuromuscular junction development;negative regulation of sodium ion transport;negative regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage;positive regulation of phosphatidylinositol 3-kinase signaling;regulation of macroautophagy;protein ubiquitination;transmission of virus;negative regulation of vascular endothelial growth factor receptor signaling pathway;neuron projection development;receptor internalization;receptor catabolic process;cellular response to UV;regulation of ion transmembrane transport;T cell activation;regulation of membrane potential;glucocorticoid receptor signaling pathway;proteasome-mediated ubiquitin-dependent protein catabolic process;ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway;development involved in symbiotic interaction;positive regulation of protein catabolic process;positive regulation of nucleocytoplasmic transport;blood vessel morphogenesis;regulation of dendrite morphogenesis;regulation of synapse organization;progesterone receptor signaling pathway;response to calcium ion;protein K63-linked ubiquitination;regulation of potassium ion transmembrane transporter activity;negative regulation of sodium ion transmembrane transporter activity
- Cellular component
- ubiquitin ligase complex;chromatin;cytoplasm;Golgi apparatus;cytosol;plasma membrane;cell cortex;apicolateral plasma membrane;dendritic spine;perinuclear region of cytoplasm;extracellular exosome;glutamatergic synapse;postsynaptic cytosol
- Molecular function
- protein binding;sodium channel inhibitor activity;protein domain specific binding;beta-2 adrenergic receptor binding;ionotropic glutamate receptor binding;ubiquitin binding;phosphoserine residue binding;phosphothreonine residue binding;ubiquitin protein ligase activity;RNA polymerase binding;proline-rich region binding